<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03650101</url>
  </required_header>
  <id_info>
    <org_study_id>P00029806</org_study_id>
    <nct_id>NCT03650101</nct_id>
  </id_info>
  <brief_title>Improving Infant Hydrocephalus Outcomes in Uganda</brief_title>
  <official_title>Improving Infant Hydrocephalus Outcomes in Uganda: Predicting Developmental Outcomes and Identifying Patients at Risk for Early Treatment Failure After ETV/CPC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CURE Children's Hospital, Uganda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neonatal postinfectious hydrocephalus (PIH) is a major public health problem in East&#xD;
      Africa.The standard treatment has long been placement of a ventriculoperitoneal shunt (VPS)&#xD;
      but these devices require life-long maintenance and nearly all fail multiple times.&#xD;
      Endoscopic Third Ventriculostomy (ETV) with Choroid Plexus Cauterization (ETV/CPC) is an&#xD;
      alternate treatment to give patients a shunt-free life. In this study, the investigators aim&#xD;
      to optimize the metrics of evaluation as quantitative prognostic indicators of treatment&#xD;
      response and long term outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2021</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bayley Scales of Infant Development, Third Edition (BSID-3), cognitive scaled score</measure>
    <time_frame>24 months of age</time_frame>
    <description>Scores on the BSID-3, which is used to evaluate infants and toddlers 1 to 42 months of age, range from 1 to 19, with higher scores indicating better performance; the mean (±standard deviation(SD)) score in the general population is 10±3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of ETV/CPC treatment failure</measure>
    <time_frame>6 months post-treatment</time_frame>
    <description>Treatment failure or success will be determined with the use of clinical and radiographic criteria.&#xD;
Treatment success will be determined as the shift in the growth of head circumference to a normal rate, as plotted on a standard growth chart; decompression of the anterior fontanel; relief of symptoms of elevated intracranial pressure, such as irritability and vomiting; resolution of down-gaze or sixth cranial nerve palsy; and a decrease or arrest in ventriculomegaly as determined on Computerized Tomography (CT).&#xD;
Treatment failure will be defined as treatment-related death or the need for a second operation for infection or for the recurrence of hydrocephalus.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cerebral oxygen metabolism</measure>
    <time_frame>pre- and post-, 6, 12 months post-treatment and 24 months of age</time_frame>
    <description>cerebral oxygen metabolism will be measured with near-infrared spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>brain volume</measure>
    <time_frame>pre-, 6, 12 months post-treatment and 24 months of age</time_frame>
    <description>brain volume will be quantitatively estimated from the head CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bayley Scales of Infant Development, Third Edition (BSID-3), cognitive scaled score at 12 months post-treatment</measure>
    <time_frame>12 months post-treatment</time_frame>
    <description>Scores on the BSID-3, which is used to evaluate infants and toddlers 1 to 42 months of age, range from 1 to 19, with higher scores indicating better performance; the mean (±standard deviation) score in the general population is 10±3.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hydrocephalus</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ETV/CPC</intervention_name>
    <description>The Endoscopic Third Ventriculostomy/Choroid Plexus Cauterization (ETV/CPC) will comprise a standard frontal approach with flexible endoscopy.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Infants less than six months old with progressive hydrocephalus&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infants less than 180 days (six months) old&#xD;
&#xD;
          -  Symptomatic hydrocephalus characterized by abnormal rate of head growth, full anterior&#xD;
             fontanel, ventriculomegaly&#xD;
&#xD;
          -  A parent or a guardian qualified by Ugandan law to give informed consent&#xD;
&#xD;
          -  Patients from Eastern, Central and Northern districts of Uganda, and in geographic&#xD;
             proximity to CURE hospital will be eligible&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age greater than six months&#xD;
&#xD;
          -  No evidence of progressive hydrocephalus&#xD;
&#xD;
          -  Patients outside of the districts specified in the inclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>180 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pei-Yi Lin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pei-Yi Lin, PhD</last_name>
    <phone>6179191308</phone>
    <email>Ivy.Lin@childrens.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthew Foster</last_name>
    <phone>6179192729</phone>
    <email>osp@childrens.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Penn State University</name>
      <address>
        <city>University Park</city>
        <state>Pennsylvania</state>
        <zip>16802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cure Children's Hospital of Uganda</name>
      <address>
        <city>Mbale</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edith Mbabazi, MD</last_name>
      <email>edith.mbabazi@cureinternational.org</email>
    </contact>
    <investigator>
      <last_name>Edith Mbabazi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Uganda</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>August 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2018</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children's Hospital</investigator_affiliation>
    <investigator_full_name>Pei-Yi Lin</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Hydrocephalus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocephalus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will not be shared with researchers outside of the study team.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

